Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase II, Randomized, Multi-center, Two Part Study of the Safety and Efficacy of Double-blind, Placebo-controlled INX-08189 in Adjunctive Treatment With Peginterferon Alfa-2a (Pegasys) and Ribavirin (Copegus) in Study Part A, and Open-label INX-08189 in Adjunctive (Interferon Free) Treatment With Daclatasvir and/or Ribavirin (Copegus) in Study Part B, in Chronically-infected HCV Genotype 2 and 3 Treatment-naive Subjects.

Next Previous
X
Search
Trial Profile

A Phase II, Randomized, Multi-center, Two Part Study of the Safety and Efficacy of Double-blind, Placebo-controlled INX-08189 in Adjunctive Treatment With Peginterferon Alfa-2a (Pegasys) and Ribavirin (Copegus) in Study Part A, and Open-label INX-08189 in Adjunctive (Interferon Free) Treatment With Daclatasvir and/or Ribavirin (Copegus) in Study Part B, in Chronically-infected HCV Genotype 2 and 3 Treatment-naive Subjects.

Status: Discontinued
Phase of Trial: Phase II

Latest Information Update: 07 Nov 2021

Price :

$35 *

Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs BMS 986094 (Primary) ; Daclatasvir; Peginterferon; Ribavirin
  • Indications Hepatitis C
  • Focus Adverse reactions; Therapeutic Use
  • Sponsors Bristol-Myers Squibb

    • Most Recent Events

    • 23 Aug 2012 Status changed from suspended to discontinued.
    • 06 Aug 2012 Status changed from recruiting to suspended as reported by ClinicalTrials.gov.
    • 01 Aug 2012 Administration of BMS 986094 has been suspended due to the emergence of a serious adverse event.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top